Aplos Medical Inc
Publicly observedEden Prairie, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Eden Prairie | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Aplos Medical Inc | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | LVDEFFEY37L9 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant2 Sept 2025Publicly observed
NIH SBIR/STTR award: Readying the commercialization of Omega device as an improved safe and efficacious treatment for drug-failed GERD patients
USD 429,295.00 · National Institute of Diabetes and Digestive and Kidney Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant2 Sept 2025Publicly observed
NIH SBIR/STTR award: Readying the commercialization of Omega device as an improved safe and efficacious treatment for drug-failed GERD patients
USD 570,706.00 · National Institute of Diabetes and Digestive and Kidney Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant1 May 2021Publicly observed
NIH SBIR/STTR award: Pivotal Clinical Study to Validate Early Outcomes of a Novel Implantable Device for Surgical Treatment of Gastroesophageal Reflux Disease
USD 1,030,000.00 · National Institute of Diabetes and Digestive and Kidney Diseases · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.